Bioinformatics holds the promise of developing personalized treatment for cancer patientsThe Pacific Northwest Research Institute (PNRI), located in Seattle, Washington USA and Indivumed GmbH (Indivumed), based in Hamburg, Germany, announced today that they have entered a strategic collaboration led by Dr. David Galas, a world renowned expert in computational biology. The collaboration is designed to harness the power of molecular and clinical cancer data for tailoring successful treatments for individual cancer patients.Indivumed's global Cancer Database and Biobank contains more than 4.5 million biological data points associated with greater than 600,000 discrete tumor, blood and urine samples obtained from more than 25,000 cancer patients. Indivumed stringently follows highly standardized processes for the collection and preservation of biospecimen samples from cancer patients, which results in the highest quality molecular and clinical datasets.
Scripps to use SOZO in Heart Failure Study
PRNewswire/ -- ImpediMed Limited (ASX: IPD), a global provider of medical technology to measure, monitor and manage fluid status and body composition, today announced that Scripps Health will use the SOZOTM device in a validation study for monitoring patients with heart failure who are currently being tracked using pulmonary artery pressure monitoring. The validation study will provide real-world data necessary for the final design of the pivotal trial.The study is being led by J. Thomas Heywood, MD, Director, Heart Failure Recovery and Research Program, and Andrew Accardi, MD, Chairman of Emergency Medicine. Both physicians are members of Scripps Health and ImpediMed's Medical Advisory Board. Dr. Heywood's patients at Scripps Green Hospital, part of the Scripps Health system, will be recruited for the study.
PRNewswire-USNewswire/ -- Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. This is the finding of a study in cancer cells and mice published August 10 in Nature. The study was led by researchers from NYU Langone Medical Center, the Dana Farber Cancer Institute at Harvard, and the University of Michigan Medical School.The results revolve around the unique ability of pancreatic cancers to scavenge for energy when oxygen and blood sugar (glucose), normally supplied by the bloodstream, are in short supply. This is the case inside tumors where abnormal cell growth quickly consumes available resources.
New Study Integrating Multiple Types of Protein Biomarkers Increases Accuracy of Early Breast Cancer Detection
PRNewswire-USNewswire/ -- A first-time study published in PLOS ONE shows that a combined assessment of multiple types of protein biomarkers in the blood offers an important advancement for detecting early breast cancer. The study, conducted by Provista Diagnostics, compared the ability of Serum Protein Biomarkers (SPBs) and Tumor-Associated Autoantibodies (TAAbs), either alone or in combination, to detect breast cancer."The study contributes critical understanding about the sensitivity and specificity advantage gained by integrating SPBs and TAAbs, to accurately detect breast cancer," said David E. Reese, Ph.D., President and CEO of Provista Diagnostics. The study entitled "Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-based Proteomic Assay to Identify Breast Cancer" is part of the broader pipeline of research studies slated for publication in 2016, exploring the use of SPBs and TAAbs in Provista's blood-based diagnostic test, Videssa® Breast.
Mallinckrodt To Acquire Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products
PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that it has entered into a merger agreement with Stratatech Corporation, a privately held regenerative medicine company focused on the development of unique, proprietary skin substitute products. Developmental products include StrataGraft regenerative skin tissue and a technology platform for genetically enhanced skin tissues. Financial terms of the transaction were not disclosed.
Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer
PRNewswire/ -- Australian oncology-focused biotechnology company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for Cantrixil (TRX-E-002-1) in ovarian cancer.The IND is a detailed regulatory filing which is required to initiate clinical studies in the United States. It has been compiled over the past twelve months, following a decision to move Cantrixil into clinical development at the Company's strategic pipeline review in August 2015.
KalVista Announces Initiation of a Phase 1 Clinical Trial of KVD818 for the Treatment of Hereditary Angioedema
PRNewswire/ --KalVista Pharmaceuticals today announced the dosing of the first subject in a first-in-human clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally delivered KVD818 in healthy volunteers. A KalVista discovery, KVD818 is a novel, potent, and selective inhibitor of plasma kallikrein in development for the prevention of attacks of edema in patients with hereditary angioedema (HAE).
PharmaMar (MCE: PHM) announces that it has received the approval from the Independent Data Monitoring Committee (IDMC) to continue with the pivotal CORAIL study of PM1183 (lurbinectedin) in patients with platinum-resistant ovarian cancer up to the recruitment of the 420 patients established in the protocol.
Vedanta Biosciences Announces Collaboration with the NYU Langone Medical Center to Develop Microbiome-Derived Immunotherapies for Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences, pioneering the development of a novel class of therapies designed to modulate pathways of interaction between the human microbiome and the host immune system, today announced that it has entered into a translational collaboration with the NYU Langone Medical Center focused on developing novel microbiome-derived immunotherapies for cancer patients being treated with checkpoint inhibitors.
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today issued the following statement regarding the ongoing investigation being conducted by the U.S. Attorney's Office for the Southern District of New York: "Valeant previously disclosed in October 2015 that the United States Attorney's Office for the Southern District of New York commenced an investigation involving Valeant. We have been fully cooperating with the authorities throughout the investigation, and we are in frequent contact and continue to cooperate with the U.S. Attorney's Office for the Southern District of New York. We do not comment on rumors about investigations, and cannot comment on or speculate about the possible course of any ongoing investigation.